NASDAQ:STLN Oncology Institute (STLN) Stock Price, News & Analysis $3.00 -0.18 (-5.66%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$3.01 +0.01 (+0.33%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Oncology Institute Stock (NASDAQ:STLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oncology Institute alerts:Sign Up Key Stats Today's Range$2.97▼$3.2750-Day Range$3.00▼$7.0552-Week Range$2.32▼$7.13Volume5.86 million shsAverage Volume5.20 million shsMarket Capitalization$305.97 millionP/E RatioN/ADividend YieldN/APrice Target$9.25Consensus RatingModerate Buy Company Overview The Oncology Institute is a physician-led provider of cancer care. Its services include medical oncology and hematology consultations, cancer treatment and infusion services, pharmacy support, and access to clinical trials. The company combines community-based clinics with care coordination and value-based care programs intended to support patients throughout treatment. It serves patients in several U.S. states, including California, Nevada, Arizona, and Florida. Founded in 2007, The Oncology Institute has expanded its network of oncology clinics and related services to provide cancer care closer to where patients live.AI Generated. May Contain Errors. Read More Oncology Institute Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreSTLN MarketRank™: 2.40571989345 of 5 starsOncology Institute scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingOncology Institute has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOncology Institute has a consensus price target of $9.25, representing about 208.3% upside from its current price of $3.00.Amount of Analyst CoverageOncology Institute has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Oncology Institute's stock forecast and price target. Earnings and Valuation0.7 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oncology Institute are expected to grow in the coming year, from ($0.27) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncology Institute is -10.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.24% of the float of Oncology Institute has been sold short.Short Interest Ratio / Days to CoverOncology Institute has a short interest ratio ("days to cover") of 5.42.Change versus previous monthShort interest in Oncology Institute has recently increased by 4.67%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncology Institute does not currently pay a dividend.Dividend GrowthOncology Institute does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest4 people have searched for STLN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oncology Institute insiders have sold 6,353.47% more of their company's stock than they have bought. Specifically, they have bought $176,273.00 in company stock and sold $11,375,733.00 in company stock.Percentage Held by Insiders4.40% of the stock of Oncology Institute is held by insiders.Percentage Held by Institutions36.86% of the stock of Oncology Institute is held by institutions.Read more about Oncology Institute's insider trading history. Receive STLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STLN Stock News HeadlinesInsider Selling: Oncology Institute (NASDAQ:STLN) Major Shareholder Sells $11,375,733.39 in StockNovember 13, 2026 | americanbankingnews.comInsider Buying: Oncology Institute (NASDAQ:STLN) Major Shareholder Purchases 48,294 Shares of Company StockNovember 11, 2026 | insidertrades.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 22 at 1:00 AM | Weiss Ratings (Ad)Oncology Institute (NASDAQ:STLN) Stock Sees Unusually High Call Option BuyingNovember 11, 2026 | americanbankingnews.comTranscript : Starling Oncology, Inc., Q3 2026 Earnings Call, Nov 05, 2026November 6, 2026 | marketscreener.comMStarling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027November 6, 2026 | seekingalpha.comStarling Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMStarling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 GuidanceNovember 5, 2026 | globenewswire.comSee More Headlines STLN Stock Analysis - Frequently Asked Questions How have STLN shares performed this year? Oncology Institute's stock was trading at $6.41 on August 7, 2026. Since then, STLN stock has decreased by 53.2% and is now trading at $3.00. How were Oncology Institute's earnings last quarter? Oncology Institute, Inc. (NASDAQ:STLN) announced its earnings results on Thursday, November, 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.06. The business had revenue of $169.77 million for the quarter. Read the conference call transcript. How do I buy shares of Oncology Institute? Shares of STLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncology Institute own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncology Institute investors own include NVIDIA (NVDA), Microvast (MVST), Amprius Technologies (AMPX), D-Wave Quantum (QBTS), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA) and BigBear.ai (BBAI). Company Calendar Last Earnings11/05/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 9 days, STLN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:STLN Previous SymbolNASDAQ:TOI CIK1799191 Webwww.starlingoncology.com Phone(562) 735-3226FaxN/AEmployees641Year FoundedN/APrice Target and Rating Average Price Target for Oncology Institute$9.25 High Price Target$10.00 Low Price Target$8.00 Potential Upside/Downside+208.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.61 million Net Margins-5.33% Pretax Margin-5.73% Return on EquityN/A Return on Assets-18.93% Debt Debt-to-Equity RatioN/A Current Ratio1.11 Quick Ratio0.82 Sales & Book Value Annual Sales$502.73 million Price / Sales0.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.37) per share Price / Book-8.11Miscellaneous Outstanding Shares101,990,000Free Float97,503,000Market Cap$305.97 million OptionableOptionable Beta0.44 The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:STLN) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredA quick test most investors failCan you defend your biggest holding? Seeking Alpha Premium gives you its Quant valuation grade versus its sect...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncology Institute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncology Institute With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.